Skip to main content
. Author manuscript; available in PMC: 2014 Sep 23.
Published in final edited form as: Autoimmunity. 2010 Aug 9;44(2):137–148. doi: 10.3109/08916934.2010.482116

Figure 5.

Figure 5

rrLeptin treated diabetics survive in the absence of exogenous insulin. BBDR rats induced to become diabetic following pIC+KRV treatment were given rrLeptin or vehicle as described in Methods. A. Kaplan Meier curve of the survival of recent onset diabetic BBDR rats treated with rrLeptin or vehicle control (p=0.0046). Rats were monitored for up to 20 days, with pump replacement 10 days following the first pump insertion. Any rat that met one of three criteria was euthanized: (1) 20% weight loss, (2) urine ketone positivity, or (3) distressed status. Median DKA free survival time was 3.7 days in the vehicle control and > 20 days in the rrLeptin group. B. rrLeptin ameliorates the rapid weight loss in new onset diabetics. Body weight changes in rats treated with rrLeptin or vehicle control. C. rrLeptin temporarily restores normoglycemia in new onset diabetics. Non-fasting blood glucose levels from the same rats shown in B. In B and C, three representative animals are shown from each group; M = male and F = female rat.